Show simple item record

dc.contributor.authorBrayne, Carolen
dc.contributor.authorWaller, Rachelen
dc.contributor.authorMurphy, Marken
dc.contributor.authorGarwood, Claire Jen
dc.contributor.authorJennings, Lukeen
dc.contributor.authorHeath, Paul Ren
dc.contributor.authorChambers, Annabelleen
dc.contributor.authorMatthews, Fionaen
dc.contributor.authorInce, Paul Gen
dc.contributor.authorWharton, Stephen Ben
dc.contributor.authorSimpson, Julie Een
dc.date.accessioned2018-10-04T11:48:14Z
dc.date.available2018-10-04T11:48:14Z
dc.identifier.issn1098-1136
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/283193
dc.description.abstractOxidative stress and oxidative DNA damage are early features of mild cognitive impairment and Alzheimer’s disease (AD), occurring before the formation of classical AD neuropathology, and resulting from an imbalance between pro- and anti-oxidants. Astrocytes play a major neuroprotective role, producing high levels of anti-oxidants including metallothionein-I and –II (MT-I/II). In the present study we characterized the immunoreactive profile of MT-I/II in the temporal cortex of the Cognitive Function and Ageing Study (CFAS) aging population-representative neuropathology cohort, and examined H2O2-modulation of MT transcription by human astrocytes. MT-I/II is primarily expressed by astrocytes in the aging brain, but is also associated with pyramidal neurons in a small proportion of cases. Astrocyte expression of MT-I/II does not correlate with Alzheimer-type pathology (Aβ plaques and neurofibrillary tangles) but does relate to astrocyte oxidative DNA damage (rs= 0.312, p= 0.006) and the astrocyte response to oxidative DNA damage in vivo (rs= 0.238, p= 0.04), and MT gene expression is significantly induced in human astrocytes response to oxidative stress in vitro (p=0.01). In contrast, neuronal MT-I/II does not relate to oxidative DNA damage or the neuronal DNA damage response, but is significantly higher in cases with high levels of local tangle pathology (p=0.007). As MT-I/II is neuroprotective against oxidative stress, modulation of MT-I/II expression is a potential therapeutic target to treat the onset and progression of cognitive impairment.
dc.languageengen
dc.publisherWiley-Blackwell
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAlzheimer's diseaseen
dc.subjectastrocyteen
dc.subjectmetallothionein-I/IIen
dc.subjectoxidative stressen
dc.titleMetallothionein-I/II expression associates with the astrocyte DNA damage response and not Alzheimer-type pathology in the ageing brainen
dc.typeArticle
prism.endingPage8
prism.publicationNameGLIAen
prism.startingPage1
prism.volume2018en
dc.identifier.doi10.17863/CAM.30557
dcterms.dateAccepted2018-05-15en
rioxxterms.versionofrecord10.1002/glia.23465en
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/en
rioxxterms.licenseref.startdate2018-05-15en
dc.contributor.orcidBrayne, Carol [0000-0001-5307-663X]
dc.contributor.orcidMatthews, Fiona [0000-0002-1728-2388]
dc.identifier.eissn1098-1136
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idMRC (G9901400)
pubs.funder-project-idMRC (G0601022)
cam.issuedOnline2018-08-10en
dc.identifier.urlhttps://onlinelibrary.wiley.com/doi/full/10.1002/glia.23465en
cam.orpheus.successThu Jan 30 10:54:19 GMT 2020 - The item has an open VoR version.*
rioxxterms.freetoread.startdate2100-01-01


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International